Clinical Trial of Human (Allogeneic) iPS Cell-derived Cardiomyocytes Sheet for Ischemic Cardiomyopathy

Myocardial Ischemia Clinical Trial

Official title:

Clinical Trial of Human (Allogeneic) iPS Cell-derived Cardiomyocytes Sheet for Ischemic

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04696328
• Other study ID #: CVSC0005
• Status: Recruiting
• Phase: Phase 1
• Start date: December 2, 2019
• Est. completion date: May 30, 2023

Study information

• Verified date: April 2021
• Source: Osaka University
• Contact: Takuji Kawamura, Ph.D
• Phone: +81-6-6879-3154
• Email: saisentan[@]tissue.med.osaka-u.ac.jp
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Targeting patients with severe ischemic cardiomyopathy, the purpose of this study is as follows: to confirm short-term efficacy by observing changes and transitions in cardiac function and clinical symptoms compared with each patient's baseline (before and after comparison) by human iPS cell-derived cardiomyocyte sheet transplantation, and to evaluate the safety and tolerability including the combined use of immunosuppressants.

Description:

The objective of this study is to confirm the efficacy and safety of a human (allogeneic) iPS cell-derived cardiomyocyte sheet in combination with an immunosuppressant for ischemic cardiomyopathy patients. The primary evaluation items will be improvement of left ventricular systolic function (LVEF) for efficacy, and safety will be assessed by blood tests, general laboratory tests, and other safety-related evaluations. Secondary evaluation items are NYHA functional evaluation, left ventricular remodeling evaluation by echocardiography, hemodynamic evaluation, physical activity function evaluation such as 6MWD and SAS, QOL, and exercise tolerance evaluation by questionnaires.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: May 30, 2023
• Est. primary completion date: May 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Patients with chronic ischemic heart disease

2. Patients with Grade III-IV NYHA Functional Classification heart failure

3. Patients who are in the state of heart failure despite maximal oral medications including digitalis, diuretics, ACE inhibitors, ARBs, beta-blockers, anti-aldosterone drugs, and oral cardiotonics

4. Patients who are 20 years of age or older at the point of consent

5. Patients at risk of worsening heart failure despite being under standard surgical treatment (coronary artery bypass surgery, mitral valve angioplasty, left ventricular angioplasty, cardiac resynchronization therapy, and percutaneous coronary intervention) for more than 3 months

6. Patients with LVEF (Echocardiography) at rest of 35% or less

7. Patients whose informed consent for clinical trial participation can be obtained from the subject himself/herself in writing

8. Patients who can continue to visit to the clinical trial site for 52 weeks after obtaining consent, continue to live in Japan, and can be expected to have data collected by NRMD/PMS

Exclusion Criteria:

1. Patients with autoimmune diseases

2. Patients with allergies or hypersensitivity to the immunosuppressant used

3. Patients with active infections

4. Patients who remain in shock due to worsening heart failure

5. Patients with irreversible organ failure other than heart

6. Patients with malignant tumors

7. Patients who are or may be pregnant

8. Patients with history of alcoholism or drug addiction within six months from the day of consent

9. Patients with allergies or hypersensitivity to animals such as cattle from which the raw materials are derived

10. Patients with severe pulmonary hypertension

11. Patients within 6 months of completion of other clinical trials at the time of enrollment

12. In addition, patients with other cardiovascular abnormalities who are determined to be unfit for this study as per the judgment of the patient enrollment study committee of physicians

Related Conditions & MeSH terms

• Ischemia
• Myocardial Ischemia

Intervention

Biological:
• Human (allogeneic) iPS cell derived-cardiomyocyte sheet
Transplantation

Locations

Country	Name	City	State
Japan	Osaka University Hospital	Suita	Osaka

Sponsors (2)

Lead Sponsor	Collaborator
Osaka University	Cuorips Inc.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number of patients with improved LVEF	The number of patients with improved LVEF by echocardiography 26 weeks postoperatively compared with preoperatively.	26 weeks
Primary	Incidence of adverse events and defects [Safety and Tolerability]	Regarding adverse events and side effects (of the adverse events, those whose causal relationship with the clinical trial product is determined to be other than "not related" will be treated as side effects.) the number of occurrences and the number of occurrence examples by event and severity will be obtained.	From postoperative to the end of the observation period (52 weeks)
Primary	Incidence of serious adverse events [Safety and Tolerability]	Regarding serious adverse events, the number of occurrences and the number of occurrence examples by event and severity will be obtained.	From postoperative to the end of the observation period (52 weeks)
Primary	Incidence of abnormal vital signs [Safety and Tolerability]	Regarding changes in vital signs(Body temperature, blood pressure (systolic, diastolic), and pulse rate), summary statistics and changes at each measurement time point will be obtained.	Before surgery, 7 days, 14 days, 4 weeks, 13 weeks, 26 weeks, 52 weeks
Primary	Incidence of abnormal general blood tests [Safety and Tolerability]	Regarding changes in general blood tests(WBC, RBC, Hb, Ht, PLT), summary statistics and changes at each measurement time point will be obtained.	Before surgery, 1 days, 7 days, 14 days, 4 weeks, 13 weeks, 26 weeks, 52 weeks
Primary	Incidence of abnormal blood biochemical tests [Safety and Tolerability]	Regarding changes in blood biochemistry tests(AST(GOT), ALT(GPT), LDH, ALP, BUN, Cre, UA, TG, T-Cho, LDL-Cho, Alb, CK, CK-MB, electrolytes (Na, K, Cl, Ca, iP, Mg), CRP, blood sugar), summary statistics and changes at each measurement time point will be obtained.	Before surgery, 1 days, 7 days, 14 days, 4 weeks, 13 weeks, 26 weeks, 52 weeks
Primary	Incidence of abnormal tumor marker tests [Safety and Tolerability]	Regarding changes in tumor marker tests(AFP, CA19-9, CEA, hCG), summary statistics and changes at each measurement time point will be obtained.	Screening, 13 weeks, 26 weeks, 52 weeks
Primary	Incidence of cardiac function clinical events such as death and hospitalization [Safety and Tolerability]	With respect to the incidence of cardiac function clinical events such as death and hospitalization, the number of cases in which the causes of death are related to heart disease and those unrelated to heart disease will be determined for cases of death.	From postoperative to the end of the observation period (52 weeks)
Secondary	Number of Responder patients 26 and 52 weeks after transplantation of this product	To comprehensively evaluate the efficacy of this product transplantation	26 and 52 weeks
Secondary	Contraction function of the entire left ventricle	To comprehensively evaluate the efficacy of this product transplantation	26 weeks
Secondary	Left ventricular remodeling (LVESVI)	Changes in left ventricular end systolic volume index (LVESVI) (echocardiography, CT (if available))	26 weeks
Secondary	Left ventricular remodeling (LVEDVI)	Changes in left ventricular end-diastolic volume index (LVEDVI) (echocardiography, CT (if available))	26 weeks
Secondary	New York Heart Association functional classification	Evaluation of the following changes and transitions before and 26 and 52 weeks after surgery. Class I to Class IV, the more severe, the higher the number.	Before surgery, 26 weeks, 52 weeks
Secondary	Specific Activity Scale (SAS)	Evaluation of the following changes and transitions before and 26 and 52 weeks after surgery. This is a quantitative evaluation of the subjective symptoms of heart failure from the viewpoint of exercise tolerance. List various daily activities for which exercise intensity [oxygen uptake or metabolic equivalents (METs)] is almost known in advance, ask whether they are possible, and exercise with the lowest activity level that was not possible is evaluated value. The higher the number, the better the condition.	Before surgery, 26 weeks, 52 weeks
Secondary	The Minnesota Living with Heart Failure Questionnaire	Evaluation of the following changes and transitions before and 26 and 52 weeks after surgery. The lower the number, the better the condition.	Before surgery, 26 weeks, 52 weeks
Secondary	36-Item Short Form Survey (SF-36)	Evaluation of the following changes and transitions before and 26 and 52 weeks after surgery. The higher the number, the better the condition.	Before surgery, 26 weeks, 52 weeks
Secondary	6-minute walking distance	Evaluation of the following changes and transitions before and 26 and 52 weeks after surgery. The higher the number, the better the condition.	Before surgery, 26 weeks, 52 weeks
Secondary	Brain natriuretic peptide (BNP)	Evaluation of the following changes and transitions.	Before surgery, 1 days, 7 days, 14 days, 4 weeks, 13 weeks, 26 weeks, 52 weeks
Secondary	N-terminal pro-brain natriuretic peptide (NT-proBNP)	Evaluation of the following changes and transitions.	Before surgery, 1 days, 7 days, 14 days, 4 weeks, 13 weeks, 26 weeks, 52 weeks
Secondary	Exercise tolerance (VO2max)	Evaluation of the following changes and transitions before and 26 and 52 weeks after surgery. Measure the maximum oxygen uptake (VO2max) using the bicycle ergometer.	Before surgery, 26 weeks, 52 weeks
Secondary	Exercise tolerance (AT)	Evaluation of the following changes and transitions before and 26 and 52 weeks after surgery. Measure the anaerobic metabolism threshold (AT) using the bicycle ergometer.	Before surgery, 26 weeks, 52 weeks
Secondary	Exercise tolerance (VE/VCO2)	Evaluation of the following changes and transitions before and 26 and 52 weeks after surgery. Measure the expiratory minute volume (VE)/the CO2 uptake (VCO2) using the bicycle ergometer.	Before surgery, 26 weeks, 52 weeks
Secondary	Cumulative number of rejections that occurred during the observation period	Cumulative number of rejections from transplant up to 26 weeks after surgery	26 weeks